A Pilot Study of Pembrolizumab Monotherapy as Maintenance Therapy in MIBC Patients Who Received Bladder-Preserving Trimodally Therapy and Achieved CR
Latest Information Update: 11 Dec 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 24 Oct 2023 Results (n=23; From January 11, 2022 to April 20, 2023) assessing the safety and efficacy of Pembrolizumab in patients with muscle-invasive bladder cancer, presented at the 48th European Society for Medical Oncology Congress.
- 18 Dec 2021 Planned primary completion date changed from 1 Nov 2024 to 7 Dec 2024.
- 18 Dec 2021 Status changed from not yet recruiting to recruiting.